Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022672 (acute tubular necrosis)
 2,175 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In the early postoperative period after renal transplantation 388 follow-up ultrasound examinations were performed in 77 patients. Over a period of 18 months standardized duplex indices (resistive index, pulsatility index) and gray-scale parameters (parenchyma/sinus index; medulla/cortex index) were sampled. These data were correlated retrospectively with clinical and pathological diagnoses. To delineate the individual course of duplex and gray-scale indices during different transplant diseases we created a new parameter: the MID (maximal index difference) which is a result of the difference between the highest index during the phase of renal dysfunction and the lowest index during the phase of normal renal function. This MID, calculated for duplex indices and for the parenchyma/sinus index, indicated significant differences in the behavior of renal transplants during the four main diseases: interstitial rejection, vascular rejection, acute tubular necrosis and Cyclosporine A nephrotoxicity. Using the MIDs, a table of cut-off values was established, which enables to differentiate retrospectively these four transplant complications with a sensitivity of 84% and specificity of 81%. In our opinion consequent follow-up examinations with duplex and gray-scale sonography should be performed, enabling sonography to become a helpful diagnostic instrument in the monitoring of renal transplants.
 ...
PMID:Follow-up study of renal transplants by duplex Doppler and gray-scale ultrasound. 139 84

Prostaglandins of the E-series (PGE) mediate a wide variety of physiologic processes and have been shown to have regulatory roles in cell immunity. Previous animal and human trials have shown lower incidence of acute rejection when prostaglandins are administered in conjunction with standard immunosuppressives. This study evaluated the effects of the PGE analogue, enisoprost (EP), in a multicenter (39 centers) prospective, randomized, double-blind trial in 374 patients undergoing renal transplantation. Groups were placebo, enisoprost 50 micrograms p.o. q.i.d. (EP-50 micrograms), and enisoprost 100 micrograms p.o. q.i.d. (EP-100 micrograms). Patients received cyclosporine, azathioprine, corticosteroids, and Minnesota antilymphocyte globulin or OKT3 according to each center's protocol. Prophylactic antibody therapy (MALG or OKT3) was not randomized. Two hundred fifty-five patients completed the 8-week study period. Of the 119 patients who were withdrawn, 73 did so because of an adverse event. Rejection episodes occurred in 98 of 374 patients (26%). There was no statistically significant difference in the incidence of rejection between placebo- and EP-treated patients (P = 0.782). There was no significant difference in episodes of cyclosporine nephrotoxicity between placebo- and EP-treatment groups (P = 0.883). There was also no difference between incidence of acute tubular necrosis, duration of initial hospitalization, or need for rehospitalization between placebo- and EP-treated groups. Administration of EP was associated with frequent adverse events including elevation of body temperature, dyspepsia, and diarrhea. Antibody-treated patients had a higher percentage of black recipients, higher mean body weight, greater cold ischemic times, fewer living-related donors, and higher panel reactivity. Patients not receiving antibody prophylaxis were better matched immunologically than those receiving either MALG or OKT3. Despite these immunologic differences, there was no significant difference in the incidence of rejection in patients who did or did not receive antibody prophylaxis. Cyclosporine toxicity was more common in MALG-treated patients (P = 0.02). Renal function was worse in antibody-treated patients. There was no detectable effect of enisoprost on the incidence of acute rejection, renal function, or hospitalization in a multicenter prospective, randomized, double-blind trial in 374 patients undergoing renal transplantation.
 ...
PMID:Enisoprost in renal transplantation. The Enisoprost Renal Transplant Study Group. 173 27

Acute tubular necrosis (ATN) after renal transplantation is related to the duration of warm and cold ischemia and leads to temporary or permanent impairment of graft function. An increased incidence of ATN has been reported since the introduction of cyclosporin A. Kidney damage resulting from hypothermic storage is generated in part during reperfusion rather than during ischemia itself. Potential mediators of the reperfusion injury are oxygen-derived free radicals. Therefore, the influence of two oxygen radical antagonists, allopurinol and superoxide dismutase, was evaluated in syngeneic rat kidney transplantation with and without concurrent administration of cyclosporin A. At 15 h cold ischemia, 28-day survival increased from 8% (no treatment) to 22% (superoxide dismutase), 33% (superoxide dismutase and allopurinol), and 73% (allopurinol). Cyclosporin A cotreatment (10 mg/kg over 14 days) resulted in survival rates of 0%, 25%, 17%, and 50% for the respective treatment groups. The results of serum creatinine values and morphological evaluation of biopsies paralleled the survival rates. Cyclosporin A nephrotoxicity was evidenced by significant serum creatinine elevations throughout the 28-day period of observation. In conclusion, allopurinol significantly protects syngeneic rat kidney transplants against a critical duration of cold ischemia. Under the conditions of this experiment, allopurinol was clearly superior to superoxide dismutase treatment. Cyclosporin A nephrotoxicity was, however, not ablated by the oxygen radical antagonists employed.
 ...
PMID:Protective effect of allopurinol and superoxide dismutase in renal isografts in cyclosporin A-treated rats. 178 Apr 91

In 66 patients with renal transplants 246 sonographic examinations were performed. The patients were divided into two groups based on their immunosuppressive protocol. Group I was treated with Cyclosporin A (CsA) and group II with azathioprin. A compensatory hypertrophy with a volume increase of 20% could be seen in nearly all grafts. During acute tubular necrosis only minimal sonographic changes could be found. In each group 16 patients developed an acute rejection episode. Sonographic signs of acute rejection were: (1) a hypoechoic enlargement of the renal pyramides; (2) an increase in cortical echogenicity; (3) an increase in graft volume greater than compensatory hypertrophy; (4) an indistinct parenchyma-pelvic border; (5) dilation of the pelvis with a parenchyma-pelvic index greater than 2.3:1 (in group II cases). Chronic rejection is characterized by graft shrinkage. No specific signs were evident. The increasing use of CsA diminishes the value of sonography in follow-up of acute rejection after kidney transplantation. Nevertheless, it is of great value for follow-up examination concerning other complications.
 ...
PMID:Value of sonography for follow-up examination after allogenic kidney transplantation. 187 74

Color Doppler sonography (CDS) detects changes in renal blood flow that may be useful in evaluating renal transplant dysfunction (RTD). To assess the performance of CDS as a clinical test, we reviewed results from 223 CDS measurements in 130 renal transplant recipients during a 26 month period. Spectral wave forms were characterized by pulsatility index (PI) (maximum frequency shift minus minimum frequency shift divided by mean frequency shift). In 27 individuals with stable renal function, mean PI was 1.80 +/- 0.23 (S.D.). Abnormal PI were subsequently defined as greater than two S.D. more than the mean (PI greater than or equal to 2.3). CDS performed during the early post-transplant period (n = 91) could not differentiate acute tubular necrosis (ATN), obstruction and rejection. Abnormal studies were seen in 35 of 46 instances of ATN and in three of obstruction. In 132 studies done after the postoperative period, CDS became abnormal during rejection episodes in only 45 of 71 instances (sensitivity rate of 63 per cent). When abnormal, CDS was highly suggestive of rejection, however (45 of 49, 92 per cent specificity). Cyclosporine toxicity was not associated with abnormal pulsatility (zero of seven). In 68 instances, CDS and conventional 99mTc DTPA renogram flow studies were performed together within 24 hours. CDS was more sensitive in detecting rejection but the difference did not reach statistical significance (25 of 36 versus 17 of 36). The major advantage of CDS over conventional radionuclide imaging relates to its shorter examination time, lower cost and portable capabilities. CDS will probably become the roentgenologic imaging modality of choice in renal transplantation.
 ...
PMID:Evaluation of renal transplant dysfunction using color Doppler sonography. 192 97

The outcome of renal transplantation in CAPD patients is still controversial since age and clinical differences often make comparison with hemodialysis patients difficult. The aim of this study was to analyse two homogeneous groups of patients, on CAPD and on hemodialysis. 18 CAPD (Group A) and 18 hemodialysis patients (Group B) were selected for a case-control analysis, matched for age, presence of acute tubular necrosis and Cyclosporine A regimen. Group A and B were not different for male/female ratio, donor age, HLA-Dr mismatches, arterial pressure, cold ischemia, or follow-up. Patient, graft survival and number of rejection episodes did not differ significantly at 1 year; serum creatinine at 6 and 12 months and CyA doses at 1 and 6 months were not different; hospitalization rates for first and subsequent admissions did not differ. Infection-free patients were 9/18 in Group A and 15/18 in Group B, with 12 episodes in Group A and 3 in Group B. Post transplant cholesterol levels showed a trend to increase in both groups and triglycerides levels to a decrease; differences in pre and post transplant in body weight were not significant at 12 months. In conclusion, the outcome of transplantation in CAPD patients is not significantly different from that in hemodialysis patients with similar clinical characteristics.
 ...
PMID:Comparison between two dialytic populations undergoing renal transplantation. 198 44

This review gives a survey of the most important tubulo-interstitial and glomerular lesions in kidney transplants. Among the tubulo-interstitial lesions subcapsular interstitial fibrosis, acute tubular necrosis, cellular tubulo-interstitial rejection and Ciclosporin associated lesions are briefly described. The review of the glomerular lesions is focused upon intraglomerular coagulation, transplant glomerulitis and transplant glomerulopathy. Among the immunocomplex diseases the preexisting glomerular lesions are stressed. Furthermore the differential diagnosis between rejection associated glomerular lesions and glomerulonephritis is discussed. Finally the prognostic significance of the different morphologic lesions is outlined based on an analysis of 500 biopsies from Basel.
 ...
PMID:[Interstitial and glomerular changes in kidney transplants]. 248 6

The pathogenesis of acute renal failure (ARF) in such common conditions as acute tubular necrosis, acute interstitial nephritis, and primary graft anuria (ischemic transplant ARF) is poorly understood. Animal models may not exactly mimic the situation in man and thus human morphologic studies are of particular importance. Non-replacement of individual sloughed tubular cells and simplification of the brush border and basolateral infoldings of tubular cells are prominent morphologic changes which correlate with the presence of renal failure. It is possible that the initial injury inhibits cell membrane synthesis, thus interfering with proximal tubular sodium reabsorption with resulting activation of the renin angiotensin system and afferent arteriolar vasoconstriction. Tubular backleak, tubular obstruction by casts and debris, and decreased glomerular ultrafiltration coefficient may also play a role. Although poorly studied until now, the renal failure in primary graft anuria may have a completely different pathogenesis from that in acute tubular necrosis and acute interstitial nephritis. Cyclosporine nephrotoxicity is an important component of primary graft anuria, as seen in many transplant centers in the 1980's.
 ...
PMID:Acute renal failure in man: pathogenesis in light of new morphological data. 330 Nov 19

The nephrotoxic effects of cyclosporine (CsA) seem to be augmented by co-existing renal injury. A high rate of prolonged delayed function (acute tubular necrosis [ATN]) and non-function (NF) has been associated with the use of CsA prior to and following renal transplantation. Cyclosporine has also been associated with a slower recovery of allograft function and poor baseline renal function even in allografts that function immediately compared with conventionally treated recipients. In 1983 we hypothesized that the rate of ATN and NF following renal transplantation could be decreased and more normal kidney function achieved if renal injury was resolved before adding the nephrotoxic effects of CsA. A group of 300 nonsplenectomized, uremic recipients have received 304 renal transplants and have been initially immunosuppressed with azathioprine, prednisone, and Minnesota antilymphoblast globulin (ALG) prior to starting maintenance CsA and prednisone. The incidence of NF has been 1.9% and the development of ATN has been 7.6% following transplantation with sequential use of ALG and CsA. Other benefits to the renal recipient have also occurred with use of this immunotherapy protocol. Renal allograft survival for recipients of first, second, and third renal allografts has been higher than that generally reported with cyclosporine and prednisone alone. Rejection episodes have been infrequent during the first six months posttransplant, as 75% and 62% of first and second renal allograft recipients have remained rejection-free. Clinically significant infectious complications were infrequent. No cadaver recipient has developed a lymphoma. Moreover, the initial hospitalization following transplantation with sequential ALG/CsA has been short and generally uncomplicated. We conclude that sequential ALG/CsA following renal transplantation provides excellent early posttransplant immunosuppression while avoiding the nephrotoxic effects of CsA and also provides the steroid and infection-sparing benefits derived from maintenance CsA therapy.
 ...
PMID:Sequential antilymphoblast globulin and cyclosporine for renal transplantation. 354 30

The use of Cyclosporine (CsA) immediately after renal transplantation may be associated with an increased incidence and duration of acute tubular necrosis (ATN) and permanent primary graft nonfunction. To avoid this potential interaction we treated recipients of primary cadaveric grafts initially with azathioprine (AZA), methylprednisolone (MP), and 5 daily doses of Minnesota antilymphoblast globulin (MAG) (postoperative days 3-7). AZA was discontinued and CsA started on day 6 if the graft was functioning by then. If ATN persisted beyond day 6, AZA and MAG (maximum 12 doses) were continued and CsA withheld until graft function was established (group 1-33 patients). This protocol is compared to our previous regimen of MAG (14 doses over the first 3 weeks), AZA and MP (group 2-68 primary cadaveric graft recipients). Improved one-year graft survival (81% vs. 60%, P less than 0.05) and patient survival (93% vs. 81%, P less than 0.05) were seen in group 1. The incidence and duration of ATN did not differ in the two groups. During the first year after transplantation more patients in group 1 were completely free of rejection episodes (40% vs. 20%, P less than 0.05) and the number of rejection episodes per patient was also lower in this group (1.0 +/- 15 vs. 1.6 +/- 49, P less than 0.05). The incidence of infections was not different in the two groups. No tumors have developed in either group. We conclude that in primary cadaveric renal transplantation the initial administration of a short course of MAG followed by CsA therapy results in excellent graft and patient survival while avoiding the potential adverse effect of CsA on an allograft already subjected to preservation injury.
 ...
PMID:Sequential use of Minnesota antilymphoblast globulin and cyclosporine in cadaveric renal transplantation. 390 29


1 2 Next >>